The Tübingen vaccine developer CureVac wants to ask the shareholders for fresh capital for the first time since going public. CureVac wants to sell five million new shares, and if there is enough demand, an increase of 15 percent is possible, as the company announced on Monday evening.
At the closing price on Monday on the US technology exchange Nasdaq of 104.50 dollars, CureVac could take up to 600 million dollars. Most of the time, however, new shares are issued at a discount to attract investors.
CureVac is working on a corona vaccine, but is still a few months away from approval. The company recently teamed up with the pharmaceutical giant Bayer to market it.
Before the start of the capital increase, the US Securities and Exchange Commission must first approve the prospectus. CureVac made a brilliant debut on the Nasdaq in August. At that time the shares were issued at $ 16, the closing price on the first day of trading was $ 55.90. Since then, the rate has almost doubled. That makes the company worth a good $ 18 billion. Before the IPO, the federal government got involved through the state bank KfW and other investors – at that time at a valuation of 1.6 billion euros.
